Ongoing Clinical Trials for Primary Hyperthyroidism
There is currently 1 ongoing clinical trial for primary hyperthyroidism, comparing two different treatment approaches for patients with overactive thyroid nodules. This trial is being conducted in the Netherlands and aims to evaluate the effectiveness and safety of radiofrequency ablation versus radioactive iodine therapy in managing hyperthyroidism caused by solitary autonomous thyroid nodules.
Clinical trial locations
Study Comparing Radiofrequency Ablation and Sodium Iodide (131I) for Treating Hyperthyroidism in Patients with Overactive Thyroid Nodules
This clinical trial focuses on comparing two treatment options for patients whose hyperthyroidism is caused by a single overactive thyroid nodule. The study is being conducted in the Netherlands and aims to determine which treatment provides better outcomes over a one-year period.
Main inclusion criteria:
- Participants must be over 18 years old
- Diagnosed with hyperthyroidism or subclinical hyperthyroidism caused by a single overactive thyroid nodule
- Blood tests showing low TSH levels with normal or elevated thyroid hormones (FT4 and FT3/T3)
- Negative test results for anti-TSH antibodies
- Confirmation of a single overactive nodule through a special scan using I-123 or I-131 that matches an ultrasound-visible nodule
- The nodule must be smaller than 50 mm and have less than 75% fluid-filled areas
- Must be eligible for both radioactive iodine treatment and radiofrequency ablation
- Must provide informed consent after understanding the study
Main exclusion criteria:
- Individuals with a history of hyperactive thyroid nodules
- Participants outside the specified age range (details not provided)
- Vulnerable populations, including children, pregnant women, or those unable to provide informed consent
Focus and goals: The trial compares two treatment approaches for managing hyperthyroidism caused by solitary thyroid nodules. Participants will be randomly assigned to receive either radiofrequency ablation or radioactive iodine therapy. The study will monitor several outcomes over a one-year period, including the development of irreversible hypothyroidism (when the thyroid becomes underactive), changes in thyroid function, nodule size reduction, and quality of life improvements. Regular follow-up assessments will occur at 6 weeks, and at 3, 6, and 12 months after treatment, involving blood tests, ultrasound scans, and questionnaires to evaluate treatment effectiveness and safety.
Investigational treatments:
Radiofrequency Ablation (RFA) uses heat generated by radio waves to destroy abnormal thyroid tissue. The procedure is guided by ultrasound to precisely target the overactive thyroid nodule. This minimally invasive approach aims to reduce the nodule size and alleviate symptoms without affecting the healthy thyroid tissue.
Radioactive Iodine (RAI), also known as sodium iodide (131I), is administered orally in capsule form at doses ranging from 0.329 to 3.7 MBq, depending on individual needs. Once taken, the radioactive iodine is absorbed by the thyroid gland, where it gradually destroys overactive thyroid cells. This treatment aims to reduce thyroid nodule activity and control hyperthyroidism by selectively targeting the problematic tissue.
Summary
Currently, there is only one ongoing clinical trial specifically for primary hyperthyroidism, taking place in the Netherlands. This study represents an important comparison between a well-established treatment (radioactive iodine) and an emerging minimally invasive alternative (radiofrequency ablation) for patients with solitary autonomous thyroid nodules. The trial’s comprehensive follow-up over one year, including assessments of thyroid function, nodule size changes, and quality of life, will provide valuable information to help guide treatment decisions for individuals with this condition. The focus on preventing irreversible hypothyroidism while effectively treating hyperthyroidism addresses an important consideration in thyroid disease management.
